Uniphar Presentation
description
Transcript of Uniphar Presentation
UniPhar Group plc
Delivery Team: Lisa Grassick; Cui Li; Matthew Maloney; Ping Shao; Theresa Xie
19th April 2010
Finance issues
Instability, Restructuring & Downsizing
Re-location
Government Regulation
Parallel Importing
Core Issues to be Addressed
“To be the leading, innovative, and cost effective provider of wellness to our employees and customers in all the markets we operate in”
Proposed Mission Statement
Become No.1 provider in the Irish
Market
Remain market leader in the area of
customer service in the face of
industrial decline and changing market
structure
Increased investment in human capital
Objectives
Internal Analysis - VIROResource Valuable Costly to Imitate Rare Organization
Exclusive rights to contracts Yes No Yes Yes
Human Capital Yes No No No
* Infrastructure Yes Yes Yes Yes
*Exclusive IT-Klug Yes Yes Yes Yes
*Customer service Yes Yes Yes Yes
Supply Chain Network Yes No Yes Yes
*Brand Yes Yes Yes Yes
Portfolio Yes Yes Yes No
UK subsidiaries Yes Yes No Yes
Banking relationship Yes Yes No Yes
Pharmacist Relationships Yes Yes Yes No
VIRO framework show competitive advantages in:
1. Customer Service2. Exclusive IT systems capabilites3. Infrastructure & Supply Chain Network4. UniPhar Brand
Internal Analysis Conclusion
Political◦ Highly regulated
industry ◦ HSE Imposing reforms
Economic◦ World Economic Climate◦ Low return on
investment◦ Devaluation in value of
property
External Analysis
SocialHealth Conscious/
Lifestyle of Public
TechnologyE-Purchasing
IncreasingCommunication
Technology Increasing
Logistical Technology
StrengthsExcellent reputation for customer service
and support.(staff training, sales teamClose ties with stakeholders
Broadly successful previous strategic directions
Wide network of customersEstablishment of UK division
Supply Chain (high standards & logistics delivery)
Underlying business model is profitableCentralised procurement/IT ordering and
management system
OpportunitiesAdvanced technology upgrades to seek
efficiencies and advanced customer solutions
Expansion of high margin medical products market
WeaknessesFinancial difficulty (liquidity)
Survivor’s syndrome (employees unrest due to redundancy)
Industrial relation issues, restructureCulture damaged
Common vision – communication issues (both vertical and horizontal)
Waste of resources.(sunk costs, relocation, ERP implementation)
Reaction Speed to changes has been too slow, organisation is not 'organic' enough to its environment
ThreatsIncreased competition from
existing competitors ( United drug, CMR) & potential competitors
(parallel imports).Changing market structure. (Merger and Acquisitions,
proposed United Drug takeover)Downturn in the economy.
Tougher regulation and policy in pharmacy sector (HSE)
SWOT Analysis
1. Integration and maximisation of
economies of scale and scope
2. Expansion of High Margin Product
Categories
3. Change management programme
4. Tackle Parallel Imports
Strategic Choice/ Action Plan
Strategic Implementation
Resources Required
Risk ManagementRisk
mitigation
Risk Identificatio
n
Risk Planning
Mapping out
Risk planning
Risk analysis
Q&A
Thank You!